Revuforj® (revumenib) FDA Approval in R/R NPM1 Mutated AML Call 10.24.25 / 2:30 PM EDT Listen to webcast Supporting Materials Revuforj® (revumenib) FDA Approval in R/R NPM1 Mutated AML Presentation 1.4 MB